AllianceBernstein’s Heron Therapeutics HRTX Stock Holding History

AllianceBernstein’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$258K	Hold	198,550	–	–	﹤0.01%	2948
2025 Q4	$258K	Hold	198,550	–	–	﹤0.01%	2968
2025 Q3	$250K	Hold	198,550	–	–	﹤0.01%	3006
2025 Q2	$411K	Hold	198,550	–	–	﹤0.01%	2756
2025 Q1	$437K	Hold	198,550	–	–	﹤0.01%	2607
2024 Q4	$304K	Hold	198,550	–	–	﹤0.01%	2871
2024 Q3	$395K	Hold	198,550	–	–	﹤0.01%	2781
2024 Q2	$695K	Buy	198,550 +33,520	+20%	+$103K	﹤0.01%	2486
2024 Q1	$457K	Sell	165,030 -28,590	-15%	-$71.9K	﹤0.01%	2621
2023 Q4	$329K	Hold	193,620	–	–	﹤0.01%	2801
2023 Q3	$199K	Hold	193,620	–	–	﹤0.01%	2965
2023 Q2	$225K	Buy	193,620 +16,720	+9%	+$29.8K	﹤0.01%	2947
2023 Q1	$267K	Hold	176,900	–	–	﹤0.01%	2816
2022 Q4	$442K	Buy	176,900 +16,100	+10%	+$51.9K	﹤0.01%	2693
2022 Q3	$679K	Hold	160,800	–	–	﹤0.01%	2496
2022 Q2	$449K	Sell	160,800 -218,500	-58%	-$877K	﹤0.01%	2719
2022 Q1	$2.17M	Buy	379,300 +250,300	+194%	+$1.83M	﹤0.01%	2038
2021 Q4	$1.18M	Sell	129,000 -14,100	-10%	-$144K	﹤0.01%	2392
2021 Q3	$1.53M	Hold	143,100	–	–	﹤0.01%	2305
2021 Q2	$2.22M	Sell	143,100 -57,752	-29%	-$919K	﹤0.01%	2132
2021 Q1	$3.26M	Hold	200,852	–	–	﹤0.01%	1813
2020 Q4	$4.25M	Hold	200,852	–	–	﹤0.01%	1586
2020 Q3	$2.98M	Sell	200,852 -70,778	-26%	-$1.1M	﹤0.01%	1624
2020 Q2	$4M	Buy	271,630 +11,000	+4%	+$181K	﹤0.01%	1451
2020 Q1	$3.06M	Buy	260,630 +135,030	+108%	+$2.54M	﹤0.01%	1431
2019 Q4	$2.95M	Buy	125,600 +3,100	+3%	+$68.6K	﹤0.01%	1738
2019 Q3	$2.27M	Hold	122,500	–	–	﹤0.01%	1857
2019 Q2	$2.28M	Sell	122,500 -37,193	-23%	-$743K	﹤0.01%	1896
2019 Q1	$3.9M	Buy	159,693 +56,493	+55%	+$1.48M	﹤0.01%	1514
2018 Q4	$2.68M	Hold	103,200	–	–	﹤0.01%	1668
2018 Q3	$3.27M	Hold	103,200	–	–	﹤0.01%	1584
2018 Q2	$4.01M	Buy	103,200 +46,900	+83%	+$1.49M	﹤0.01%	1404
2018 Q1	$1.55M	Sell	56,300 -54,600	-49%	-$1.24M	﹤0.01%	2000
2017 Q4	$2.01M	Buy	110,900 +45,100	+69%	+$735K	﹤0.01%	1854
2017 Q3	$1.06M	Hold	65,800	–	–	﹤0.01%	2243
2017 Q2	$911K	Buy	65,800 +10,100	+18%	+$146K	﹤0.01%	2335
2017 Q1	$836K	Buy	55,700 +7,000	+14%	+$96.9K	﹤0.01%	2325
2016 Q4	$638K	Hold	48,700	–	–	﹤0.01%	2471
2016 Q3	$839K	Buy	48,700 +1,300	+3%	+$24.1K	﹤0.01%	2308
2016 Q2	$856K	Hold	47,400	–	–	﹤0.01%	2295
2016 Q1	$900K	Sell	47,400 -586,961	-93%	-$11.6M	﹤0.01%	2159
2015 Q4	$16.9M	Buy	634,361 +26,874	+4%	+$719K	0.01%	761
2015 Q3	$14.8M	Buy	607,487 +560,087	+1,182%	+$18.7M	0.01%	784
2015 Q2	$1.48M	Buy	47,400 +43,600	+1,147%	+$820K	﹤0.01%	2042
2015 Q1	$55K	Buy	3,800 +2,800	+280%	+$31.6K	﹤0.01%	3126
2014 Q4	$10K	Hold	1,000	–	–	﹤0.01%	3307
2014 Q3	$8K	Sell	1,000 -1,000	-50%	-$9.31K	﹤0.01%	3310
2014 Q2	$25K	Buy	+2,000	New	+$23.9K	﹤0.01%	3202

Other funds holding HRTX

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

AllianceBernstein's HRTX Position: Q1 2026 in Review

AllianceBernstein held its Heron Therapeutics (HRTX) position steady in Q1 2026 at 198,550 shares worth $258K. The position accounts for ﹤0.01% of the portfolio, ranked #2948.

AllianceBernstein first reported a position in HRTX in Q2 2014 and has held it in 48 quarters since. The position peaked at $16.9M in Q4 2015. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

AllianceBernstein held 198,550 shares of Heron Therapeutics worth $258K as of Q1 2026.
AllianceBernstein left its Heron Therapeutics share count unchanged in Q1 2026.
Heron Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q1 2026, its #2948 holding.
AllianceBernstein first reported a position in Heron Therapeutics in Q2 2014 and has held it in 48 quarters since.
AllianceBernstein's Heron Therapeutics position peaked at $16.9M in Q4 2015.
167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.